APOE ε4与创伤性脑出血患者进展性出血性损伤的相关性
这项前瞻性研究纳入123例初始接受保守治疗的创伤性脑出血患者,按随访CT分为进展性出血性损伤(PHI)组和非PHI组,用PCR和测序确定APOE基因型。结果显示60例(48.8%)发生PHI,APOE ε4、INR升高和血糖≥10 mmol/L是PHI的独立危险因素,但APOE ε4与创伤性凝血病和患者结局无关。
要点
- APOE ε4是创伤性脑出血后进展性出血性损伤的独立危险因素(OR 5.14)。
- INR升高和血糖≥10 mmol/L也是PHI的独立危险因素。
- APOE ε4与创伤性凝血病及患者结局无关。
核心结论
- APOE ε4、INR升高和血糖≥10 mmol/L是创伤性脑出血患者发生进展性出血性损伤的预测因素。
- APOE ε4与创伤性凝血病和患者结局无关。
研究设计与样本
- 前瞻性队列研究,纳入123例初始接受保守治疗的创伤性脑出血患者。
- 根据随访CT将患者分为PHI组和非PHI组,采用PCR和测序确定APOE基因型,多因素logistic回归分析PHI预测因素。
主要发现
- 60例(48.8%)患者发生PHI。
- PHI组APOE等位基因分布与非PHI组显著不同(p = 0.008)。
- PHI组晚期手术率显著高于非PHI组(24.4% vs 11.4%,p = 0.002)。
- 多因素logistic回归显示APOE ε4(OR 5.14,95% CI 2.40-11.62)、INR升高(OR 3.57,95% CI 1.61-8.26)和血糖≥10 mmol/L(OR 3.88,95% CI 1.54-10.77)是PHI的独立危险因素。
关键数值与推荐
- APOE等位基因总体频率:E2/2 0%、E2/3 14.6%、E3/3 57.8%、E2/4 2.4%、E3/4 22.8%、E4/4 2.4%。
- PHI组等位基因分布:E2/2 0%、E2/3 5.7%、E3/3 22.8%、E2/4 2.4%、E3/4 16.3%、E4/4 1.6%。
临床怎么用
- 对创伤性脑出血保守治疗患者,可检测APOE基因型、INR和血糖以评估PHI风险。
- APOE ε4携带者、INR升高或血糖≥10 mmol/L者应加强影像随访,警惕PHI及晚期手术需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The intracranial hematoma volume in patients with traumatic brain injury is a key parameter for the determination of the management approach and outcome. Apolipoprotein E (APOE) ε4 is reported to be a risk factor for larger hematoma volume, which might contribute to a poor outcome. However, whether APOE ε4 is related to progressive hemorrhagic injury (PHI), a common occurrence in the clinical setting, remains unclear. In this study, the authors aimed to investigate the association between the APOE genotype and occurrence of PHI. METHODS: This prospective study included a cohort of 123 patients with traumatic intracerebral hemorrhage who initially underwent conservative treatment. These patients were assigned to the PHI or non-PHI group according to the follow-up CT scan. A polymerase chain reaction and sequencing method were carried out to determine the APOE genotype. Multivariate logistic regression analysis was applied to identify predictors of PHI. RESULTS: The overall frequency of the alleles was as follows: E2/2, 0%; E2/3, 14.6%; E3/3, 57.8%; E2/4, 2.4%; E3/4, 22.8%; and E4/4, 2.4%. Thirty-four patients carried at least one allele of ε4. In this study 60 patients (48.8%) experienced PHI, and the distribution of the alleles was as follows: E2/2, 0%; E2/3, 5.7%; E3/3, 22.8%; E2/4, 2.4%; E3/4, 16.3%; and E4/4, 1.6%, which was significantly different from that in the non-PHI group (p = 0.008). Additionally, the late operation rate in the PHI group was significantly higher than that in the non-PHI group (24.4% vs 11.4%, p = 0.002). Multivariate logistic regression identified APOE ε4 (OR 5.14, 95% CI 2.40-11.62), an elevated international normalized ratio (OR 3.57, 95% CI 1.61-8.26), and higher glucose level (≥ 10 mmol/L) (OR 3.88, 95% CI 1.54-10.77) as independent risk factors for PHI. Moreover, APOE ε4 was not a risk factor for the coagulopathy and outcome of the patients with traumatic intracerebral hemorrhage. CONCLUSIONS: The presence of APOE ε4, an elevated international normalized ratio, and a higher glucose level (≥ 10 mmol/L) are predictors of PHI. Additionally, APOE ε4 is not associated with traumatic coagulopathy and patient outcome.
引用
- Wan X, Gan C, You C, et al. Association of APOE ε4 with progressive hemorrhagic injury in patients with traumatic intracerebral hemorrhage. J Neurosurg. 2019. PMID: 31323634. doi:10.3171/2019.4.JNS183472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。